Track 11 Collaboration and Externalization in R&D @ BioIT World, April 30, 2014 Seaport World Trade Center, Boston, MA
Reporter: Aviva Lev-Ari, PhD, RN
Collaboration and Externalization in R&D
4:00 Co-Presentation: Informatics Paradox: Separating and Collaborating in Life Science
Sarah Blendermann, Senior Director, Chemistry & Pharmacology, Business
Technology, Pfizer
Rick Somes, Senior Director, Acquisitions, Divestitures and Restructuring
R&D Business Technology, Pfizer
The organization was running operations and discovery while separating data and systems. Collaboration and segregation were key components of
the informatics required to successfully meet an IPO timeline. A long-term collaboration agreement means ties between the organizations will remain,
requiring longer-term technical solutions for granular security, collaboration, and data sharing.
In REAL TIME
Possibilities:
Sell a sunsidiary for Animal health
IPO
Spin off a subsidiary
Key issues for R%D – 70% of applications, 800 applications between Whole Pfizer and Animal Health.
COLLABORATE
Build a Plan
Thinks to consider 0 Have a documen: Data, people, IT resources
- Application Separation
- License Separations – Vendors: SAS, 800 applications in the postfolio
- Data sepation:
- Compound Inventory – Legal Agreements
- FDA Library
- sales complexity
- IPO complexity -Hard
Begin Separation
- IPO day
- Separation day Zoetis vs. Pfizer
- Application Separation: Human Health vs Animal Health
- Transition Services Agreement – to support shared Applications
- Data Separations Research Commom Compound
- IP, who own experimental research data
- Encumbrances: Collaborations
- Legal agreements
- Collaborations Application to share data
Two separate companies, Partnering on Enchanting future PROVENANCE Issues
4:30 Towards the Intelligent and Automated Analytical Laboratory
Dave Hartsough, Ph.D., Executive Director, Sites, Benchtop, & Validation R&D Informatics, Amgen
This presentation will provide an update on the progress of the Allotrope Foundation towards delivering an open Framework solution for managing analytical data throughout its lifecycle and will include details on the deliverables, timelines, and results from completed proof-of-concept applications based upon the initial proposal and analysis presented in 2013.
Dave Hartsough in REAL TIME
Data id MOST valuable asset
If 3% error rate it addds 30% more cost
EMPLOYEES are the most valuable not data
ALLOTROPE: A foundation
- Subject matter experts
- Osthus – s Gernam company
- Secretairiate
SW incomplete, no standard formats, incompatible Metadata
Effects: Need for a Framework
Solution Automated documents
- open documents standard – existing standards
- Metadata Repository
- Reusable SW componenets
Ready for archiving
Proof-of-Concept applications (2014)
PoC Instruent SW Integration, PoC Archive, Metadata repository, PoC Viewer
Heading up toward: Being SOurce agnostict
- Commercial ELN/LIMS,
- Commercial Archive
- Commercial Viewer
GOAL: Reduce cost of interaction with CRO
Example: One instance of one workflow: 20,000 hours per year saving, increasing accuracy, quality of data
First PoC deployed to one of member company
BENEFITS OF BEING A MEMBER IN THIS INTERNATIONAL CONSORTIUM
Instrument & software Vendors
http://partners.alllotrope.org
Regulatory engagement FDA Liaison to be assign to work wiht the Consorsium.
Access data complexity – reduced
Framework is based on dtandard
ROI
5:00 Growing our Innovation Capability from the Inside-Out: AstraZeneca’s Journey to a New a Way of Working
Scott Wilkins, Ph.D., Enterprise Innovation Director, AstraZeneca
Scott Wilkins in REAL TIME
$4 billion spent on R&D every year
25 Billion in Sales
Partnering and collaborations are KEY
21 century- NETWORKS are key to survival
Use R&D resources and Collaborations
2010 – R&D Culture Initiatives – Professional skills, communications, grow collaborative behaviors
2011 – Evaluated and Piloted R&D Collaborations tools Globally enterprise -wide R&D
2012 0 Innovation Capabilities: Culture, technology, partners, Processes
Information Pyramid
InnoCENTIVE -consuting with NASA
- iSOLE Coach
- Challenge Owner
- Solver evaluation & Award
2012 – 5,000 participants in Challenges launched, 500 ideas, $1 million Awarded to Winners
Enterprise Collaboration
OUTCOMES: Going to AstraZeneca OPEN Innovations 10,000 Scientists around the glovbr
- New molecule Profiling
- Novel Disease Indications for AstraZeneca Competition
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.